- Home
- AXIL vs CTSO Comparison
AXIL vs CTSO Comparison
Compare AXIL & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXIL
- CTSO
- Stock Information
- Founded
- AXIL 2015
- CTSO 1997
- Country
- AXIL United States
- CTSO United States
- Employees
- AXIL N/A
- CTSO N/A
- Industry
- AXIL Package Goods/Cosmetics
- CTSO Medical/Dental Instruments
- Sector
- AXIL Consumer Discretionary
- CTSO Health Care
- Exchange
- AXIL Nasdaq
- CTSO Nasdaq
- Market Cap
- AXIL 43.9M
- CTSO 51.6M
- IPO Year
- AXIL N/A
- CTSO N/A
- Fundamental
- Price
- AXIL $9.09
- CTSO $1.15
- Analyst Decision
- AXIL
- CTSO Strong Buy
- Analyst Count
- AXIL 0
- CTSO 3
- Target Price
- AXIL N/A
- CTSO $4.67
- AVG Volume (30 Days)
- AXIL 22.9K
- CTSO 147.4K
- Earning Date
- AXIL 04-09-2025
- CTSO 03-06-2025
- Dividend Yield
- AXIL N/A
- CTSO N/A
- EPS Growth
- AXIL 135.54
- CTSO N/A
- EPS
- AXIL 0.25
- CTSO N/A
- Revenue
- AXIL $26,554,439.00
- CTSO $37,739,531.00
- Revenue This Year
- AXIL N/A
- CTSO $9.20
- Revenue Next Year
- AXIL N/A
- CTSO $11.64
- P/E Ratio
- AXIL $35.94
- CTSO N/A
- Revenue Growth
- AXIL N/A
- CTSO 1.80
- 52 Week Low
- AXIL $3.54
- CTSO $0.70
- 52 Week High
- AXIL $14.00
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- AXIL 71.30
- CTSO 55.74
- Support Level
- AXIL $6.53
- CTSO $1.06
- Resistance Level
- AXIL $10.75
- CTSO $1.61
- Average True Range (ATR)
- AXIL 0.82
- CTSO 0.13
- MACD
- AXIL 0.26
- CTSO 0.01
- Stochastic Oscillator
- AXIL 65.05
- CTSO 29.34
About AXIL AXIL Brands Inc. Common Stock
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.